Mathieu FIORE
University Hospital, Bordeaux
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mathieu FIORE as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:05 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06234813 · Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro StudyUniversity Hospital, Bordeaux · completed · Glanzmann Thrombasthenia · principal investigator
- N/ANCT04595617 · Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)University Hospital, Bordeaux · completed · Glanzmann Thrombasthenia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:05 UTC. The ranking covers the 200 most relevant of 114 PubMed records, and a shared surname and initials can bring in a namesake. All 114 on PubMed
- A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.N Engl J Med · 19991,103 citationsRCR 36.6
- 398 citationsRCR 23.5
- 369 citationsRCR 15.3
- Gender differences in smoking cessation.J Consult Clin Psychol · 1999316 citationsRCR 11.3
- Development and validation of the Wisconsin Smoking Withdrawal Scale.Exp Clin Psychopharmacol · 1999262 citationsRCR 8.8
- A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction.PLoS Genet · 2008216 citationsRCR 5.6
- Development of the Brief Wisconsin Inventory of Smoking Dependence Motives.Nicotine Tob Res · 2010190 citationsRCR 6.9
- A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.Arch Gen Psychiatry · 2009189 citationsRCR 6.3
- Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution.Ann Surg Oncol · 2011187 citationsRCR 6.0
- 176 citationsRCR 7.0